Gene therapy-based strategies for spinal muscular atrophy—an Asia-Pacific perspective
Abstract Onasemnogene abeparvovec has been life-changing for children with spinal muscular atrophy (SMA), signifying the potential and progress occurring in gene- and cell-based therapies for rare genetic diseases. Hence, it is important that clinicians gain knowledge and understanding in gene thera...
Main Authors: | Michelle A. Farrar, Loudella Calotes-Castillo, Ranil De Silva, Peter Barclay, Lani Attwood, Julie Cini, Monica Ferrie, Didu S. Kariyawasam |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2023-11-01
|
Series: | Molecular and Cellular Pediatrics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40348-023-00171-5 |
Similar Items
-
Landscape of Spinal Muscular Atrophy Newborn Screening in the United States: 2018–2021
by: Kshea Hale, et al.
Published: (2021-06-01) -
Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy
by: Didu S. T. Kariyawasam, et al.
Published: (2019-08-01) -
Very severe spinal muscular atrophy (Type 0)
by: Suleiman Al Dakhoul
Published: (2017-01-01) -
Identification of Novel CSF-Derived miRNAs in Treated Paediatric Onset Spinal Muscular Atrophy: An Exploratory Study
by: Arlene M. D’Silva, et al.
Published: (2023-01-01) -
Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic Review
by: Karolina Aragon-Gawinska, et al.
Published: (2023-06-01)